HEPREGEN

Hepregen Corporation is pursuing applications of its microliver platform for acute and chronic toxicity as well as for understanding the metabolism of drugs in the liver. Applications in the pharmaceutical industry may well extend beyond toxicity and metabolism to include utility in drug discovery, disease modeling (obesity, infectious disease, diabetes), in silico models, and toxicogenomics. Hepregen is actively engaged in industrial collaborations to validate the microliver platform in a wide spectrum of applications. The combined markets for Hepregen's microliver platform is approximately a billion dollars annually.